Leiner Teetered Toward Bankruptcy As FDA Investigated Testing Fraud
This article was originally published in The Tan Sheet
Executive Summary
Whistleblowers' allegations of stability data manipulation at Leiner Health Products prompted the firm's rapid fall from a leading provider of private-label OTC drugs and dietary supplements to a property bought by a competitor in a bankruptcy court auction